Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy
Acta Haematologica · 2024
DOI: 10.1159/000540572 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Haematologica, 2024. Verfasst von Alessandra Iurlo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Aniline Compounds, Nitriles, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Introduction
Up to 30% of CML patients will require a therapeutic change during follow-up due to intolerance and/or resistance to first-line tyrosine kinase inhibitor (TKI) approach. In this context, bosutinib (BOS) has not only demonstrated its efficacy, but also presents a favorable safety profile, without comorbid conditions representing an absolute contraindication to its use.
Methods
To gain further into BOS treatment in real life, we conducted a retrospective analysis on the outcome of CML patients receiving BOS in 18 hematological centers, all belonging to the “REL” (Lombard Hematology Network).
Results
Of 546 regularly followed CML cases, a total of 132 patients were reported as being treated with BOS, most frequently (62.9%) in second line. Interestingly, most patients (63.6%) switched to BOS due to intolerance to the previous TKI, while resistance to the last treatment was reported in the remaining 36.4% of patients. Despite a permanent discontinuation rate of 18.9%, over 80% of patients achieved at least a major molecular response and seven cases were able to attempt treatment-free remission.
Conclusion
Although in this survey BOS represented the preferred option especially in patients intolerant rather than resistant to previous TKIs, we confirmed that BOS represents a safe and effective therapeutic option beyond the first line in the real-life setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Hematology and Bone Marrow Transplant Unit, ASST Ospedale Papa Giovanni XXIII, Bergamo, Italy.
- Division of Hematology1, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Hematology Institute, Hospital of Cremona, Cremona, Italy.
Zitieren
APA
Iurlo, A., Bucelli, C., Intermesoli, T., Elena, C., D'Adda, M., Agostani, E., Fiamenghi, C., Maffioli, M., Orofino, N., Lunghi, F., Gardellini, A., Carraro, M. C., Inzoli, A., Gigli, F., Palazzolo, R., Bertolli, V., Cattaneo, D., Pungolino, E. M., & Gambacorti-Passerini, C. (2024). Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy. Acta Haematologica. https://doi.org/10.1159/000540572
Vancouver
Iurlo A, Bucelli C, Intermesoli T, Elena C, D'Adda M, Agostani E, et al. Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy. Acta Haematologica. 2024. doi:10.1159/000540572
BibTeX
@article{Iurlo2024,
author = {Iurlo, Alessandra and Bucelli, Cristina and Intermesoli, Tamara and Elena, Chiara and D'Adda, Mariella and Agostani, Elena and Fiamenghi, Cristina and Maffioli, Margherita and Orofino, Nicola and Lunghi, Francesca and Gardellini, Angelo and Carraro, Maria Cristina and Inzoli, Alessandro and Gigli, Federica and Palazzolo, Roberto and Bertolli, Vanda and Cattaneo, Daniele and Pungolino, Ester Maria and Gambacorti-Passerini, Carlo},
title = {Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000540572}
}
EUVIMED